Malin Corp plc (MLC) EUR0.001

Sell:€9.60Buy:€10.10No change

Prices delayed by at least 15 minutes
Sell:€9.60
Buy:€10.10
Change:No change
Prices delayed by at least 15 minutes
Sell:€9.60
Buy:€10.10
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Malin Corporation PLC is focused on investing in life sciences companies. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. It is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.

Key people

Neil McLoughlin
General Counsel, Company Secretary
Fiona Dunlevy
Executive Director
David Dobrosky
Senior Analyst
Peter A. Schwartzman
Member of Senior Management Team
Liam Daniel
Non-Executive Chairman of the Board
Luke Corning
Non-Executive Director
Jean-Michel Cossery
Non-Executive Director
Kirsten Aarup Drejer
Non-Executive Director
Owen P. Hughes
Non-Executive Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Ireland
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    IE00BVGC3741
  • Market cap
    €165.49m
  • Employees
    3
  • Shares in issue
    18.89m
  • Exchange
    Irish Stock Exchange
  • Index
    ISEQ Overall Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.